Large glycomic studies of immunoglobulin G and totalplasma glycosylation have shown biomarker potential in IBD and couldhelp determine disease mechanisms and therapeutic treatment choice.Hitherto, the glycosylation signatures of plasma immunoglobulin A,an important immunoglobulin secreted into the intestinal mucin, haveremained undetermined in the context of IBD. The gene discussed is MUC3A; the disease is inflammatory bowel disease.